Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Blood Cancer Journal|December 15, 2020
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myelomaYanyan Gu, Benjamin G Barwick, Mala Shanmugam, et al.Annals of the New York Academy of Sciences|May 3, 2003
Dendritic cell function in vivo during the steady state: a role in peripheral toleranceRalph M Steinman, Daniel Hawiger, Kang Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myelomaAriel Anguiano, Sascha A Tuchman, Chaitanya Acharya, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 23, 2005
Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferonJacques Banchereau, Hideki Ueno, Madhav Dhodapkar, et al.Blood|April 4, 2002
The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cellsCarole L Berger, Douglas Hanlon, Daniel Kanada, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.Blood|May 27, 2008
First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee, Madhav Dhodapkar, John D Shaughnessy, et al.Blood|October 7, 2006
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan, Bart Barlogie, Varant Arzoumanian, et al.British Journal of Haematology|May 30, 2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 studySundar Jagannath, Jacob Laubach, Ellice Wong, et al.Pageof 4